Atrial Fibrillation, Falls, and a Prior GI Bleed: Choosing Anticoagulation
A 78-year-old woman with hypertension, type 2 diabetes, and a prior TIA is seen 3 months after atrial fibrillation was diagnosed. She has had two mechanical falls in the past year, neither causing injury, and a lower-GI bleed 2 years ago from angiodysplasia that was treated endoscopically with no recurrence. Her medications are metoprolol, amlodipine, and metformin. Weight 57 kg, creatinine 1.6 mg/dL, estimated GFR 30 mL/min/1.73 m², platelets 140,000/µL, hemoglobin 11.2 g/dL. CHA₂DS₂-VASc is 6 and HAS-BLED is 4. She lives alone, drives locally, and asks whether she can "just take aspirin" because her sister bled badly on warfarin.
1. Recommend a specific anticoagulant and dose, and justify the dose using the criteria that apply to this patient. Explain why aspirin alone is not an acceptable substitute.
Read the worked answer
Recommendation: apixaban 2.5 mg orally twice daily.
Dose-reduction reasoning. Full-dose apixaban is 5 mg twice daily, reduced to 2.5 mg when at least two of three criteria are present: age ≥80 years, weight ≤60 kg, serum creatinine ≥1.5 mg/dL.
- Age 78 → does not qualify
- Weight 57 kg → qualifies
- Creatinine 1.6 mg/dL → qualifies
Two of three criteria are met, so the reduced dose is correct. Underdosing (2.5 mg in a patient meeting only one criterion) is a common error and is associated with increased stroke without a meaningful bleeding benefit.
Why not aspirin. Aspirin monotherapy reduces stroke by roughly 20% versus ~65% for dose-adjusted warfarin and the DOACs; the residual absolute stroke risk in a CHA₂DS₂-VASc 6 patient is substantial (roughly 6–8% per year untreated). Aspirin is also not meaningfully safer for GI bleeding. Dual antiplatelet therapy is likewise inferior to anticoagulation for AF and carries more bleeding.
Alternatives. Rivaroxaban 15 mg daily with the evening meal (CrCl 30) or dose-adjusted warfarin are acceptable, but apixaban has the most favorable bleeding profile in this age/renal group. Dabigatran should be avoided at CrCl 30.
2. The patient and her daughter both cite the falls and the old GI bleed as reasons to avoid anticoagulation. How do you handle this, and what concrete risk-mitigation steps do you take?
Read the worked answer
Reframe the trade-off with numbers. Falls are a weak predictor of intracranial hemorrhage - a community-dwelling older adult needs on the order of hundreds of falls per year before the modeled risk of subdural hematoma outweighs the stroke reduction from anticoagulation. Two falls without injury is not a contraindication. In contrast, her untreated annual stroke risk is high and a major stroke carries ~30% mortality plus permanent disability. Framing it as "which risk do you prefer to carry" rather than "anticoagulation is unsafe" moves the conversation.
HAS-BLED is a modification tool, not a veto. It flags factors to correct, not reasons to withhold:
- Falls: gait/balance physical therapy, home safety evaluation, vision check, review of sedating or BP-lowering agents, orthostatic vitals
- GI bleeding: avoid NSAIDs and aspirin; consider a proton pump inhibitor; treat iron deficiency; recheck hemoglobin at 1 month then periodically; counsel on warning symptoms
- Renal function: check creatinine/CrCl at least every 6–12 months (more often if ill), since dose appropriateness changes
- Adherence: once-daily options help if twice-daily dosing is a barrier, though that is not a problem here
Document a shared decision, provide a written plan for bleeding (hold the drug, seek care), and give the daughter the same information. Avoid the common failure mode of deploying aspirin as a "compromise" - it offers little stroke protection while retaining bleeding risk.
3. Eight months later she presents with melena, hemoglobin 7.4 g/dL, and BP 92/60 mmHg while still taking apixaban. Outline your acute priorities and how you would decide about restarting anticoagulation.
Read the worked answer
Acute priorities (resuscitation before reversal debates).
- Stabilize: two large-bore IVs, crystalloid, crossmatch and transfuse (restrictive threshold ~7 g/dL, higher with active massive bleeding or cardiac ischemia), reverse any hypotension, hold antihypertensives.
- Reverse the anticoagulant if bleeding is life-threatening or cannot be controlled: andexanet alfa is specific for apixaban; 4-factor PCC is the practical alternative where andexanet is unavailable. Reversal is not indicated for mild bleeding that stops with local measures.
- Localize and treat: urgent endoscopy after resuscitation; hold apixaban at least until hemostasis is achieved.
- Interrupt, don't abandon: most AF patients resume anticoagulation after GI bleeding once hemostasis is confirmed (typically 7–14 days), because the stroke risk re-emerges quickly. The decision hinges on whether the bleed source was definitively treated (e.g., angiodysplasia, ulcer, tumor) and whether a reversible cause existed.
Cheap wins on restart. Treat H. pylori if present, continue PPI, avoid NSAIDs/antiplatelets, consider switching to warfarin with good time-in-range if recurrent bleeding on a DOAC, or left atrial appendage occlusion if bleeding is uncontrollable and anticoagulation is truly precluded. Document the reasoning with the patient - "never again" and "same drug tomorrow" are both usually wrong.